Article Details
Retrieved on: 2024-03-26 18:36:24
Tags for this article:
Click the tags to see associated articles and topics
Summary
Novo Nordisk collaborates with Nvidia in a biopharma venture to accelerate drug discovery using AI, potentially affecting Novo's stock value as noted by The Motley Fool. The venture involves peptide hormones and semaglutide, with interest from Novo Holdings A/S and the Novo Nordisk Foundation.
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here